<DOC>
	<DOC>NCT00818441</DOC>
	<brief_summary>This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (&lt;100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known EGFR activating mutation; or patients with HER 2 amplification or mutation.</brief_summary>
	<brief_title>Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Advanced adenocarcinoma of lung, measurable disease Nonsmoker, or former light (less than 10 pack years and stopped at least 15 years); OR patients with known EGFR activating mutation regardless of smoking status ECOG(Eastern Cooperative Oncology Group) 01. Cohort B (select sites only): patients with HER2 amplified or HER2 mutationpositive NSCLC; may have had prior therapy Active brain metastases Prior systemic therapy for advanced disease in Cohort A only. Cohort B can have had any number of prior lines of systemic therapy. known EGFR wild type NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>lung cancer adenocarcinoma HER2</keyword>
</DOC>